Abstract
The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real-world evidence on prescribed medicine use, safety, costs and cost-effectiveness in Australia. The platform comprises Medicare-eligible people who are ≥18 years and residing in New South Wales (NSW), Australia, any time during 2005-2020, with linked data on dispensed prescription medicines (Pharmaceutical Benefits Scheme), health service use (Medicare Benefits Schedule), emergency department visits (NSW Emergency Department Data Collection), hospitalisations (NSW Admitted Patient Data Collection), cancer notifications (NSW Cancer Registry), fact and cause of death (National Death Index). Data are currently available to 2022, with approval to update the cohort and data collections annually.
The platform includes 7.4 million unique people across all years, covering 36.9% of the Australian adult population; the overall population increased from 4.8M in 2005 to 6.0M in 2020. As of 1 January 2019 (the last pre-pandemic year), the cohort had a mean age of 48.7 years (51.1% female), with most people (4.4M, 74.7%) residing in a major city. In 2019, 4.4M people (73.3%) were dispensed a medicine, 1.2M (20.5%) were hospitalised, 5.3M (89.4%) had a GP or specialist appointment, and 54 003 people died. Anti-infectives were the most prevalent medicines dispensed to the cohort in 2019 (43.1%), followed by nervous system (32.2%) and cardiovascular system medicines (30.2%).
The MedIntel Data Platform creates opportunities for national and international research collaborations and enables us to address contemporary clinically- and policy-relevant research questions about quality use of medicines and health outcomes in Australia and globally.
Five Key Points
The Medicines Intelligence (MedIntel) Data Platform is a purpose-built, real-world data resource designed to generate evidence on prescribed medicine use, safety, costs and cost-effectiveness in Australia
This is a whole of population anonymised linkage of medicine and health records of Medicare-eligible adults (≥18 years) residing in Australia’s most populous state, New South Wales, from 2005 onwards
The platform comprised 7.4M unique people across all years, representing 36.9% of the Australian adult population; the population increased from 4.8M in 2005 to 6.0M in 2020
As of 1 January 2019 (the last pre-pandemic year), the cohort had a mean age of 48.7 years (51.1% female), with most people (4.4M, 74.7%) residing in a major city
The MedIntel Data Platform creates unique research opportunities for national and international research collaborations exploring population-level medicine use and outcomes
Plain Language Summary The Medicines Intelligence (MedIntel) Data Platform is a new linked data resource established to generate evidence on prescribed medicine use, safety, costs, and cost-effectiveness in Australia. It adheres to best practice privacy principles, with no identifying information available to researchers. The platform comprises Medicare-eligible people who are ≥18 years and residing in New South Wales (NSW), Australia, any time during 2005-2020, with linked data on dispensed prescription medicines, Medicare services, emergency department visits, hospitalisations, cancer notifications, and deaths. In total, the platform includes 7.4 million unique people across all years, covering 36.9% of the Australian adult population. As of 1 January 2019 (the last pre-pandemic year), the cohort had a mean age of 48.7 years (51.1% female), with most people (4.4M, 74.7%) residing in a major city. In 2019, 4.4M people (73.3%) were dispensed a medicine (most commonly anti-infective, nervous system, and cardiovascular medicines), 1.2M (20.5%) were hospitalised, 5.3M (89.4%) had a GP or specialist appointment, and 54 003 people died. Data are available until 2022 with approval for annual updates. This platform creates opportunities for national and international research collaborations and enables us to address important questions about quality use of medicines and health outcomes.
Competing Interest Statement
SAP is a member of the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee. The views expressed in this paper to not represent those of either Committee. CMV is a member of the PHSREC but was not present during discussion of the MedIntel Data Platform protocol. In the past three years, LD has received educational grants from Indivior and Seqirus for unrelated work. All other authors have no conflicts of interest to declare.
Funding Statement
This research data platform was established with funding from the UNSW Sydney Research Infrastructure Scheme and is supported by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence (grant number: 1196900). HZ is supported by a UNSW Scientia Program Award and a NHMRC-European Union Collaborative Research Grant (007048). MOF is supported by a Future Leader Fellowship from the National Heart Foundation of Australia (105609). XC is supported by a NHMRC Postgraduate Scholarship (2005259). BD is supported by a Cancer Institute NSW Early Career Fellowship (ECF1381). AH is supported by a NSW Health Early-Mid Career Fellowship. AS is supported by a NHMRC Early Career Fellowship (1158763).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
New South Wales (NSW) Population and Health Services Research Ethics Committee (PHSREC) gave ethical approval for this work (approval number 2020/ETH02273). Australian Institute of Health and Welfare (AIHW) Human Research Ethics Committee gave ethical approval for this work (approval number EO2021/1/1233). Individual research projects conducted under this ethical approval require that a study-specific protocol be approved by PHSREC and additional personnel be approved by AIHW. The PHSREC and AIHW ethical approvals permit annual updates of the study population and additional years of data for each person already included in the study population.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵‡ joint first authors
Data Availability
The MedIntel Data Platform was developed using best-practice governance and access criteria and we welcome national and international research collaborations. Specific requirements for researchers wishing to undertake projects using the platform are available on our website (https://unsw.to/medinteldp)
